Ciprofloxacin / Dexamethasone (Otic)

Mechanism

Pharmacological Class and Group

Topical otic association of an antibiotic from the fluoroquinolone family (Ciprofloxacin) with a high potency fluorinated synthetic glucocorticoid (Dexamethasone).

Mechanism of Action

The drug combines rapid bactericidal control with the inhibition of the local inflammatory cascade in the external auditory canal or middle ear:

• Ciprofloxacin: Selectively inhibits the bacterial enzymes DNA gyrase (topoisomerase II) in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria. By blocking the first, it prevents the supercoiling of bacterial DNA necessary for cell replication; By inhibiting the second, it interferes with the separation of replicated DNA during cell division, inducing genome fragmentation and rapid bacterial death.
• Dexamethasone: Diffuses passively through the cell membrane of keratinocytes and inflammatory cells of the ear mucosa. It binds to the glucocorticoid receptor (GR-alpha), inducing its nuclear translocation. There, it inhibits the transcriptional activity of nuclear factor NF-κB and activating protein 1 (AP-1), decreasing the synthesis of proinflammatory cytokines (IL-1, IL-6, TNF-α) and reducing the synthesis of prostaglandins and leukotrienes by inducing the expression of lipocortin-1 (annexin-A1).

Coverage Profile in Otitis Externa and Media

This combination is optimized against the most prevalent pathogens of the external auditory canal (EAC) and middle ear:

Topical Therapeutic Spectrum: Pseudomonas aeruginosa and Staphylococcus aureus

Unlike topical aminoglycosides, the combination of ciprofloxacin and dexamethasone completely lacks cochlear or vestibular ototoxicity, allowing its safe use in the presence of tympanic perforation or intratympanic ventilation tubes.

Pharmacokinetics

High Resolution Pharmacokinetics

• Rout of administration: Exclusively local otic instillation.
• Systemic Absorption: Virtually undetectable. In pediatric patients treated for OMAt with standard doses (4 drops per ear, twice a day for 7 days), the maximum plasma concentrations of ciprofloxacin and dexamethasone are below the limit of analytical quantification (< 0.05 ng/mL), preventing systemic effects of corticotherapy or fluoroquinolone.
• Distribution and Local Action: The suspension vehicle (optimized viscosity) allows the drug to cover the entire EAC mucosa or penetrate through the tympanic perforation into the middle ear cleft.

Indicators and dose

Clinical Indications and Off-Label Uses

• Acute Otitis Externa (AEO): Diffuse bacterial infection of the external auditory canal in adults and pediatric patients older than 6 months with intact tympanic membrane.
• Acute Otitis Media with tympanostomy tubes (OMAt): Treatment of otorrhea in children with patent ventilation tubes.
• Chronic Suppurative Otitis Media (CSOM): Microbiological and anti-inflammatory control in patients with chronic tympanic perforation and active otorrhea.
• Granulomas of the middle ear and EAC (off-label): Reduction of inflammatory granulation tissue secondary to friction of prostheses or persistent chronic otitis.

Dosage and Clinical Adjustment

Critical Administration Instructions:

• Warm the bottle between your hands before instillation to avoid thermal (caloric) stimulation of the vestibular system, which can trigger acute dizziness or nausea if the cold liquid penetrates through a tympanic perforation.
• Keep your head tilted for at least 5 minutes after application to maximize contact of the drug with the structures of the external and middle ear.

Adjustment in Renal or Hepatic Failure: No type of dosage adjustment is required due to the local administration route and the absence of systemic serum levels.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Known hypersensitivity to ciprofloxacin, other fluoroquinolones or dexamethasone.
• Active viral infections of the EAC or middle ear, including infections with varicella-zoster virus (Ramsay Hunt) or herpes simplex.
• Otic fungal infections (primary otomycosis due to Aspergillus niger or Candida albicans), since dexamethasone can enhance the proliferation of hyphae.

Relative Contraindications

• Presence of middle ear cholesteatoma (requires urgent surgical resolution; topical therapy is only limited to controlling temporary bacterial superinfections).

Adverse Effects (ADR) and Specific Toxicity

• Frequent (1%-10%): Transient local discomfort in the ear after instillation (pruritus, stinging, sensation of a blocked ear).
• Uncommon (0.1%-1%): Persistent otorrhea, peeling of the skin of the external auditory canal, local erythema, appearance of fungal superinfection (iatrogenic otomycosis due to prolonged use of corticosteroids).
• Rare (<0.1%): Paresthesias of the auditory canal, transient conductive hearing loss due to the accumulation of remains of the suspension in the tympanic membrane.

Prolonged Use Alert: Otomycosis and Epithelial Atrophy

The uninterrupted use of this otic suspension for more than 10-14 days can drastically alter the commensal microbiota of the EAC, favoring the opportunistic proliferation of filamentous fungi and yeasts, in addition to inducing atrophy of the cutaneous epithelium of the EAC due to the effect of dexamethasone. If the symptoms of otorrhea or pain do not improve after 7 days of optimal treatment, a fungal smear should be performed and the topical corticosteroid should be discontinued.

Drug Interactions of Clinical Relevance

• Due to the absence of relevant systemic absorption, no clinically significant interactions have been documented with drugs administered orally or parenterally.
• Concomitant administration with other ear drops with markedly acidic or alkaline pH is not recommended, as they may alter the stability of ciprofloxacin suspension.

Safety in Pregnancy and Breastfeeding

• Pregnancy: FDA Category C. Use during pregnancy is justified if the clinical benefit outweighs the theoretical risks, considering that systemic exposure after otic administration is negligible.
• Breastfeeding: Compatible. Ciprofloxacin or dexamethasone is not expected to be excreted in human milk in measurable quantities following otic application.